Current Funding Opportunities — November 2017

1) Minority-Patient Derived Xenograft (PDX) Development and Trial Center (PDTC) Network (U54)
(RFA-CA-17-032)

SPONSOR: National Cancer Institute

***Synopsis*:** This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

Receipt Date: January 18, 2018

2) Feasibility and Planning Studies for Development of Specialized Programs for Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)
(RFA-CA-17-033)

SPONSOR: National Cancer Institute

***Synopsis*:** This funding opportunity announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.

Receipt Date: January 18, 2018

3) Immuno-Oncology Translational Network (IOTN): Cancer Immunotherapy Research Projects (U01)
(RFA-CA-17-045)

SPONSOR: National Cancer Institute

Synopsis: This funding opportunity announcement (FOA) will establish an Immuno-Oncology Translation Network (IOTN) with the overall goal of accelerating research advances through collaborative team science approaches to improve immunotherapy outcomes for diverse cancers that are either resistant or develop resistance immunotherapies. Specifically, this strategy is expected to discover new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.

Receipt Date: January 16, 2018